174 related articles for article (PubMed ID: 35830974)
1. Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review.
Archwamety A; Ruangchira-Urai R; Akewanlop C; Korphaisarn K
Thorac Cancer; 2022 Sep; 13(17):2539-2541. PubMed ID: 35830974
[TBL] [Abstract][Full Text] [Related]
2. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
3. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
4. [Pulmonary lymphoepithelioma-like carcinoma with expression of Epstein-Barr virus and PD-L1].
Avilés-Salas A; Vélez-Valle A; Bryon-Gallego A; Arrieta O
Medicina (B Aires); 2023; 83(2):319-323. PubMed ID: 37094205
[TBL] [Abstract][Full Text] [Related]
5. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.
Wu Z; Xian X; Wang K; Cheng D; Li W; Chen B
Front Oncol; 2021; 11():626566. PubMed ID: 33981599
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
[TBL] [Abstract][Full Text] [Related]
8. EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.
Narayanan A; Knollmann FD; Walby JAS; Lim S; Gandara DR; Riess JW
Clin Lung Cancer; 2019 May; 20(3):e238-e241. PubMed ID: 30679078
[No Abstract] [Full Text] [Related]
9. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary Lymphoepithelioma-like Carcinoma.
Sathirareuangchai S; Hirata K
Arch Pathol Lab Med; 2019 Aug; 143(8):1027-1030. PubMed ID: 30672338
[TBL] [Abstract][Full Text] [Related]
11. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
12. Expression of PD-L1 in EBV-associated malignancies.
Li X; Zhang W
Int Immunopharmacol; 2021 Jun; 95():107553. PubMed ID: 33765613
[TBL] [Abstract][Full Text] [Related]
13. Analysis of clinical features, treatment, and prognosis of primary Xlymphoepithelioma-like carcinoma of the lung.
Hu HY; Long L; Dai SA; Yan GQ; Huang Y; He J
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(24):9416-9425. PubMed ID: 36591850
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
[TBL] [Abstract][Full Text] [Related]
15. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma.
Fan Y; Shan Q; Gong J; Qin J; Lu H
Front Mol Biosci; 2021; 8():736940. PubMed ID: 34760925
[No Abstract] [Full Text] [Related]
16. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
19. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
20. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
